LONDON, June 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the General Meeting held today were duly passed on a poll, the results of which are set out below.

Resolution	Votes for	% of votes cast		Votes against	% of votes cast		Votes total
1. Authority to allot shares	86,113,803	94.70	%	4,820,196	5.30	%	90,933,999
2. Disapplication of pre-emption rights	86,117,638	94.66	%	4,860,361	5.34	%	90,977,999

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

For further information, please contact:

Verona Pharma plc	Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer	info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser  and UK Broker)	Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Verona Pharma plc via Globenewswire